<DOC>
	<DOCNO>NCT00100802</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high energy x-ray kill tumor cell . Drugs use chemotherapy , temozolomide lomustine , work different way stop growth tumor cell , either kill cell stop divide . Giving radiation therapy together temozolomide lomustine surgery may kill remain tumor cell . PURPOSE : This phase II trial study well give radiation therapy together temozolomide lomustine work treat young patient newly diagnose glioma .</brief_summary>
	<brief_title>Radiation Therapy , Temozolomide , Lomustine Treating Young Patients With Newly Diagnosed Gliomas</brief_title>
	<detailed_description>OBJECTIVES : - Compare event-free survival pediatric patient newly diagnose high-grade glioma treat adjuvant radiotherapy temozolomide follow temozolomide lomustine historical control . - Determine toxicity regimen patient . - Correlate MGMT p53 expression tumor tissue outcome patient treat regimen . - Correlate polymorphism GSTP1 , GSTM1 , GSTT1 gene GSTP1 protein expression tumor survival patient treat regimen . OUTLINE : This pilot , multicenter study . - Chemoradiotherapy : Patients receive oral temozolomide daily day 1-42 . Patients also undergo concurrent radiotherapy daily day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 , 36-40 . Patients undergo prior gross total resection also undergo boost radiotherapy daily day 43-47 . - Maintenance chemotherapy : Four week completion chemoradiotherapy , patient receive oral temozolomide daily day 1-5 oral lomustine day 1 . Treatment repeat every 42 day 6 course absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 50-100 patient accrue study within 1-1.5 year .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm , newly diagnose highgrade glioma 1 follow histology : Anaplastic astrocytoma Glioblastoma multiforme Gliosarcoma Primary spinal cord malignant glioma allow No primary brainstem tumor Has undergone surgical resection biopsy tumor within past 31 day Preoperative postoperative brain MRI without gadoliniumcontrast OR preoperative postoperative spine MRI spinal cord primary Postoperative MRI require patient undergo biopsy No evidence neuraxis dissemination Spine MRI cerebrospinal fluid cytology require clinically indicated PATIENT CHARACTERISTICS : Age 3 21 Performance status Karnofsky 50100 % ( patient &gt; 16 year age ) Lansky 50100 % ( patient ≤ 16 year age ) Life expectancy At least 8 week Hematopoietic Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 ( transfusion independent ) Hemoglobin ≥ 8 g/dL ( transfusion allow ) Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT ≤ 2.5 time ULN Albumin ≥ 2 g/dL Renal Creatinine ≤ 1.5 time ULN OR Creatinine clearance radioisotope glomerular filtration rate ≥ low limit normal Pulmonary No evidence dyspnea rest No exercise intolerance Pulse oximetry ≥ 94 % ( determination clinically indicate ) Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study participation Able swallow oral medication Seizures allow provide well controlled anticonvulsant No hypersensitivity temozolomide PRIOR CONCURRENT THERAPY : Biologic therapy No prior biologic agent Chemotherapy No prior chemotherapy Endocrine therapy Prior corticosteroid allow No concurrent corticosteroid antiemetic Concurrent corticosteroid allow treatment increase intracranial pressure Radiotherapy No concurrent radiotherapy use cobalt60 Surgery See Disease Characteristics Other No prior treatment No concurrent phenobarbital cimetidine No concurrent cotrimoxazole Pneumocystis carinii pneumonia prophylaxis study chemoradiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>childhood spinal cord neoplasm</keyword>
</DOC>